Optimising Diffusion Weighted MRI for Imaging Metastatic and Myeloma Bone Disease and Assessing Reproducibility

Overview

Journal Eur Radiol

Specialty Radiology

Date 2011 Apr 8

PMID 21472473

Citations 58

Authors

C Messiou

D J Collins

V A Morgan

N M deSouza

Affiliations

Soon will be listed here.

Abstract

Objectives: To establish normal bone marrow values of apparent diffusion coefficient (ADC) over an age range, compare them with metastatic and myelomatous involvement, to establish reproducibility and to optimise b values.

Methods: The ADCs of bone marrow in 7 volunteers (mean age 29.7 years), 34 volunteers (mean age 63.3 years) and 43 patients with metastatic and myelomatous involvement (mean age 65.5 years) were measured. In 9 volunteers diffusion weighted MRI was repeated within 7 days. b values were derived to optimise contrast between normal and pathological marrow.

Results: The mean ADC of bone marrow in younger volunteers was significantly higher than that of older volunteers. The coefficient of reproducibility was 14.8%. The ADC mean of metastatic and myeloma bone disease was 1054 + / -456 x 10⁻⁶mm²s⁻¹. An ADC threshold of 655 × 10(-6) mm(2)s(-1) separated normal and abnormal marrow with a sensitivity and specificity of 90% and 93% respectively. Contrast between normal and abnormal marrow was optimal at b = 1389 smm(-2).

Conclusion: The reproducibility of ADC measurements in bone is equivalent to published data for soft tissue with a high sensitivity and specificity for separating abnormal from age matched normal bone marrow. A b value of around 1,400 smm(-2) is optimal for imaging bone marrow.

Citing Articles

F-FDG PET/CT and MRI in the Management of Multiple Myeloma: A Comparative Review.

Mesguich C, Hulin C, Latrabe V, Lascaux A, Bordenave L, Hindie E Front Nucl Med. 2024; 1:808627.

PMID: 39355637 PMC: 11440970. DOI: 10.3389/fnume.2021.808627.

Present and future of whole-body MRI in metastatic disease and myeloma: how and why you will do it.

Lecouvet F, Chabot C, Taihi L, Kirchgesner T, Triqueneaux P, Malghem J Skeletal Radiol. 2024; 53(9):1815-1831.

PMID: 39007948 PMC: 11303436. DOI: 10.1007/s00256-024-04723-2.

Repeatability of quantitative individual lesion and total disease multiparametric whole-body MRI measurements in prostate cancer bone metastases.

Donners R, Candito A, Blackledge M, Rata M, Messiou C, Koh D Br J Radiol. 2023; 96(1151):20230378.

PMID: 37660399 PMC: 10607420. DOI: 10.1259/bjr.20230378.

Evaluation of MRI in the diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors in comparison with the reference standard somatostatin-receptor-PET/CT.

Ingenerf M, Rubenthaler J, Wenter V, Zacherl M, Volter F, Winkelmann M Front Oncol. 2023; 13:1194152.

PMID: 37655102 PMC: 10465364. DOI: 10.3389/fonc.2023.1194152.

Diffusion-Weighted MRI for Treatment Response Assessment in Osteoblastic Metastases-A Repeatability Study.

Eveslage M, Rassek P, Riegel A, Maksoud Z, Bauer J, Gorlich D Cancers (Basel). 2023; 15(15).

PMID: 37568573 PMC: 10417276. DOI: 10.3390/cancers15153757.

References

Reese T, Heid O, Weisskoff R, Wedeen V . Reduction of eddy-current-induced distortion in diffusion MRI using a twice-refocused spin echo. Magn Reson Med. 2003; 49(1):177-82. DOI: 10.1002/mrm.10308. View

Reischauer C, Froehlich J, Koh D, Graf N, Padevit C, John H . Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations. Radiology. 2010; 257(2):523-31. DOI: 10.1148/radiol.10092469. View

Yeung D, Wong S, Griffith J, Lau E . Bone marrow diffusion in osteoporosis: evaluation with quantitative MR diffusion imaging. J Magn Reson Imaging. 2004; 19(2):222-8. DOI: 10.1002/jmri.10453. View

Koh D, Collins D . Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007; 188(6):1622-35. DOI: 10.2214/AJR.06.1403. View

Luboldt W, Kufer R, Blumstein N, Toussaint T, Kluge A, Seemann M . Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology. 2008; 249(3):1017-25. DOI: 10.1148/radiol.2492080038. View

Griffith J, Yeung D, Antonio G, Wong S, Kwok T, Woo J . Vertebral marrow fat content and diffusion and perfusion indexes in women with varying bone density: MR evaluation. Radiology. 2006; 241(3):831-8. DOI: 10.1148/radiol.2413051858. View

Wilkins B . Histology of normal haemopoiesis: bone marrow histology. I. J Clin Pathol. 1992; 45(8):645-9. PMC: 495136. DOI: 10.1136/jcp.45.8.645. View

Sugahara T, Korogi Y, Kochi M, Ikushima I, SHIGEMATU Y, Hirai T . Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999; 9(1):53-60. DOI: 10.1002/(sici)1522-2586(199901)9:1<53::aid-jmri7>3.0.co;2-2. View

Goudarzi B, Kishimoto R, Komatsu S, Ishikawa H, Yoshikawa K, Kandatsu S . Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with (11)C-methionine PET and bone scintigraphy. Magn Reson Imaging. 2010; 28(3):372-9. DOI: 10.1016/j.mri.2009.12.008. View

10.

Messiou C, deSouza N . Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: A biomarker for treatment response monitoring. Cancer Biomark. 2010; 6(1):21-32. DOI: 10.3233/CBM-2009-0116. View

11.

Hatipoglu H, Selvi A, Ciliz D, Yuksel E . Quantitative and diffusion MR imaging as a new method to assess osteoporosis. AJNR Am J Neuroradiol. 2007; 28(10):1934-7. PMC: 8134234. DOI: 10.3174/ajnr.A0704. View

12.

Herneth A, Philipp M, Naude J, Funovics M, Beichel R, Bammer R . Vertebral metastases: assessment with apparent diffusion coefficient. Radiology. 2002; 225(3):889-94. DOI: 10.1148/radiol.2253011707. View

13.

Griffith J, Yeung D, Antonio G, Lee F, Hong A, Wong S . Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy. Radiology. 2005; 236(3):945-51. DOI: 10.1148/radiol.2363041425. View

14.

Baur A, Huber A, Ertl-Wagner B, Durr R, Zysk S, Arbogast S . Diagnostic value of increased diffusion weighting of a steady-state free precession sequence for differentiating acute benign osteoporotic fractures from pathologic vertebral compression fractures. AJNR Am J Neuroradiol. 2001; 22(2):366-72. PMC: 7973927. View

15.

Koh D, Blackledge M, Collins D, Padhani A, Wallace T, Wilton B . Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol. 2009; 19(11):2728-38. DOI: 10.1007/s00330-009-1469-4. View

16.

Gauvain K, McKinstry R, Mukherjee P, Perry A, Neil J, Kaufman B . Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J Roentgenol. 2001; 177(2):449-54. DOI: 10.2214/ajr.177.2.1770449. View

17.

Gutzeit A, Doert A, Froehlich J, Eckhardt B, Meili A, Scherr P . Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol. 2010; 39(4):333-43. DOI: 10.1007/s00256-009-0789-4. View

18.

Tang G, Lv Z, Tang R, Liu Y, Peng Y, Li W . Evaluation of MR spectroscopy and diffusion-weighted MRI in detecting bone marrow changes in postmenopausal women with osteoporosis. Clin Radiol. 2010; 65(5):377-81. DOI: 10.1016/j.crad.2009.12.011. View

19.

Lee K, Sud S, Meyer C, Moffat B, Chenevert T, Rehemtulla A . An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res. 2007; 67(8):3524-8. DOI: 10.1158/0008-5472.CAN-06-4236. View

20.

Lee K, Bradley D, Hussain M, Meyer C, Chenevert T, Jacobson J . A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia. 2007; 9(12):1003-11. PMC: 2134897. DOI: 10.1593/neo.07954. View